Valuation: Bicycle Therapeutics plc

Market Cap 276M 242M 226M 207M 389M 26.44B 394M 2.68B 1.05B 13.06B 1.04B 1.01B 45.13B P/E 2026 *
-1.65x
P/E 2027 * -1.82x
Enterprise Value -236M -208M -193M -178M -333M -22.66B -338M -2.3B -897M -11.19B -887M -868M -38.66B EV / Sales 2026 *
-13.8x
EV / Sales 2027 * -8.27x
Free-Float
6.21%
Yield 2026 *
-
Yield 2027 * -
1 day-0.76%
1 week-5.65%
Current month-7.43%
1 month-5.42%
3 months-16.31%
6 months-40.35%
Current year-44.56%
1 week 3.87
Extreme 3.87
4.22
1 month 3.87
Extreme 3.87
4.52
Current year 3.87
Extreme 3.87
7.34
1 year 3.87
Extreme 3.87
9.16
3 years 3.87
Extreme 3.87
28.67
5 years 3.87
Extreme 3.87
62.08
10 years 3.87
Extreme 3.87
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Date Insider Type Main position Quantity % Market Cap.
15/7/26 Free

Chief Technology Officer

60,000 0.1580%
15/7/26 Free

CHIEF PROD & SUPPLY CHAIN OFF

60,000 0.1580%
15/7/26 Free

Chief Operating Officer

60,000 0.1580%
Change 5-day change 1-year change 3-year change Capi.($)
-0.63%-5.65%-54.41%-84.08% 276M
-2.25%+1.55%+50.84%+70.04% 56.19B
-1.32%-0.97%+38.41%+77.52% 54.83B
+0.93%-0.12%-18.24%-14.15% 23.04B
-0.40%-3.61%+2.90%+390.39% 22.7B
-0.21%+0.84%+22.48%-7.92% 20.23B
0.00%+3.00%+27.41%-29.52% 17.83B
-0.97%+0.89%+37.28%+539.62% 15.65B
-6.69%-5.11%+166.00%+304.89% 15.24B
-0.14%-0.55%+25.73%+181.16% 14.03B
Average -1.19%-0.52%+29.84%+142.79% 24B
Weighted average by Cap. -1.30%+0.41%+37.54%+131.85%

Financials

2026 *2027 *
Net sales 17.08M 15.02M 13.98M 12.84M 24.11M 1.64B 24.43M 166M 64.9M 809M 64.13M 62.75M 2.8B 15.52M 13.65M 12.7M 11.67M 21.91M 1.49B 22.2M 151M 58.98M 735M 58.28M 57.02M 2.54B
Net income -159M -139M -130M -119M -224M -15.21B -227M -1.54B -603M -7.51B -596M -583M -25.96B -164M -144M -134M -123M -231M -15.68B -234M -1.59B -621M -7.74B -614M -601M -26.76B
Net Debt -512M -450M -419M -385M -723M -49.1B -732M -4.98B -1.95B -24.24B -1.92B -1.88B -83.8B -404M -355M -331M -304M -570M -38.76B -578M -3.93B -1.54B -19.14B -1.52B -1.48B -66.15B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
29/07/26 USD 3.925 -0.63% 126,664
27/07/26 USD 3.950 +2.07% 303,823
24/07/26 USD 3.870 -6.97% 572,862
23/07/26 USD 4.160 -1.19% 154,162
22/07/26 USD 4.210 +1.20% 154,246
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.950USD
Average target price
13.57USD
Spread / Average Target
+243.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock